Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 478.78% and ...

North Dakota lawmakers on Thursday will hear testimony on a bill to lower the price of insulin drugs and supplies for residents.

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo ...

Summit Partners has hired Ricardo Gonzalez as a partner on the firm’s growth products and services team.

Advocates celebrate 2023 legislation capping insulin prices for people on the state employee health insurance plan in a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

With the close of 2024 and the launch of a new year, we can take a moment to look back at what was another eventful, ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

Eli Lilly and Company has invested more than $20 billion in its manufacturing capabilities since 2020 to help meet high ...